Ovasave®, antigen-specific regulatory T-cells for refractory Crohn's disease
Ovalbumin-specific type 1 regulatory T cells (Tregs, Ovasave®) are IL-10–producing Tregs indicated for the treatment of refractory Crohn's disease.
This clinical trial demonstrated tolerability to the treatment. The dose of 1x10^6 cells induced a clinical response, and some patients were in remission for 5 weeks after treatment. The effect is time-limited, thus, some patients received a 2nd dose which again proved tolerable and clinically beneficial.